Rigel Pharmaceuticals Inc (RIGL.OQ)
23 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|55||2014||President, Chief Executive Officer, Director|
|50||2010||Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary|
|2016||Executive Vice President, Chief Commercial Officer|
|54||2016||Chief Marketing Officer|
|40||2017||Interim Principal Accounting|
- BRIEF-Rigel Pharmaceuticals Says Expects To Report About $94.3 Mln Cash, Cash Equivalents, Short-Term Investments As Of March 31, 2018
- BRIEF-Rigel Announces Pricing Of Public Offering Of Common Stock
- BRIEF-Rigel Intends To Offer & Sell Up To 15 Mln Shares Of Its Stock In Underwritten Public Offering
- BRIEF-Rigel Pharmaceuticals NDA For Tavalisse Approved By FDA
- FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder